Antiviral therapy for human immunodeficiency virus infections.

摘要: Depending on the stage of their intervention with viral replicative cycle, human immunodeficiency virus inhibitors could be divided into following groups: (i) adsorption (i.e., CD4 constructs, polysulfates, polysulfonates, polycarboxylates, and polyoxometalates), (ii) fusion plant lectins, succinylated or aconitylated albumins, betulinic acid derivatives), (iii) uncoating bicyclams), (iv) reverse transcription acting either competitively substrate binding site dideoxynucleoside analogs acyclic nucleoside phosphonates) allosterically a nonsubstrate non-nucleoside transcriptase inhibitors), (v) integration inhibitors, (vi) DNA replication (vii) antisense oligodeoxynucleotides Tat antagonists), (viii) translation ribozymes), (ix) maturation protease myristoylation glycosylation finally, (x) budding (assembly/release) inhibitors. Current knowledge, including therapeutic potential, these various is discussed. In view potential clinical utility, problem virus-drug resistance possible strategies to circumvent this are also addressed.